Karyopharm Therapeutics reported $31.71M in Gross Profit on Sales for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
TG Therapeutics TGTX:US USD 77K 15K
Abbott ABT:US USD 5.5B 283M
Amgen AMGN:US USD 5.09B 28M
AstraZeneca AZN:LN USD 8.7B 168M
Astrazeneca AZN:US USD 8.7B 168M
Biocryst Pharmaceuticals BCRX:US USD 77.05M 4.84M
Bristol Myers Squibb BMY:US USD 8.89B 21M
Eli Lilly And LLY:US USD 5.75B 391.2M
GlaxoSmithKline GSK:LN GBP 5.2B 244M
Johnson & Johnson JNJ:US USD 15.94B 56M
Karyopharm Therapeutics KPTI:US USD 31.71M 3.45M
MacroGenics MGNX:US USD 71.31M 32.72M
Merk MRK:US USD 10.47B 610M
Nektar Therapeutics NKTR:US USD 15.79M 2.86M
Novartis NOVN:VX USD 9.16B 21M
Novartis NVS:US USD 9.16B 21M
Pfizer PFE:US USD 14.47B 2.08B
Regeneron Pharmaceuticals REGN:US USD 2.87B 255.4M
Roche Holding ROG:VX 22.04B 696M
Takeda 4502:JP JPY 760.58B 63.72B
Ultragenyx Pharmaceutical RARE:US USD 98.03M 15.96M
YTE INCY:US USD 872.94M 98.92M